Redenlab partners with BDCRC to support new NIH-funded Batten disease research
A newly formed research network focused on Batten disease, a rare and inherited brain disorder that primarily affects…
Clinical trial/studies
Latest content
Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research
Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research
Redenlab’s Chief Science Officer, Adam P. Vogel, PhD, leads groundbreaking study on speech analysis for neurodegenerative diseases
MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a…
Childhood apraxia of speech clinical trial
Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic…
Researchers working towards finding a new treatment for Spinocerebellar Ataxia Type 1 (SCA1)
Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination…
The FA App
Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to…
TRACK-FA Study
Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance,…
Professor Angela Morgan leads the Translational Centre for Speech Disorders in groundbreaking NHMRC CRE research program
Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that…
Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)
Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA…
Redenlab shines in Huberman Podcast, unveiling cannabis study and speech analysis expertise
MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The…
Redenlab selected for world-first international collaboration investigating neurofilament light chain and voice for diagnosing dementia
Redenlab are partnering with Monash university, University of Melbourne, Eastern Health, and Invicta to deliver this world-first collaboration…
The L16HTHOUSE Study
L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays…
Dietary fat supplement trial for A-T
Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts…
Temporary Assessment of Language in Kabuki Syndrome (TALK) Study
Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate…
ARIAS: Zooming in on eye-based biomarkers for Alzheimer’s
Scientists are turning to retinas as a potential screening target for early signs of Alzheimer’s, an incurable neurodegenerative…
Redenlab awarded new clinical trial with Top 10 Pharma company
Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma…
SpeechATAXIA- a multinational, multilanguage consortia for speech in hereditary ataxias – powered by Redenlab
SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.
Redenlab supporting new randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Redenlab is supporting a new long term open label extension study in Friedreich ataxia
Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics…
Redenlab chosen for new multinational natural history study in Dentatorubral-pallidoluysian atrophy (DRPLA)
Redenlab Inc, the speech neuroscience company delivering insights in communication testing, announces that it has been selected by…
Redenlab supporting Larimar Therapeutics in Phase 1 SAD Clinical Trial
Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled,…
Redenlab supporting PTC Theraputics in Global Phase 3 Clinical Trial
Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in…
How important is stability in your speech measures?
In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and…
